Anebulo Pharmaceuticals voluntarily delisting from Nasdaq, terminating SEC registration effective Feb 27, 2026

Anebulo Pharmaceuticals, Inc.

Board approved voluntary delisting from Nasdaq and deregistration with SEC on Feb 5, 2026; Nasdaq notified Feb 6.
Form 25 to be filed on or about Feb 17; delisting expected effective Feb 27, 2026.
Form 15 to be filed on or about Feb 27 certifying fewer than 300 record holders, suspending SEC reporting.
Company is in compliance with Nasdaq rules; delisting decision based on cost of public company burdens outweighing benefits.
Following delisting, trading will occur only in privately negotiated sales or on the OTC market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.